The downfall of 23andMe?
Finshots Daily
00:00
The Potential Downfall of 23andMe: False Positives, Data Security, and Drug-Making Ambitions
This chapter explores the potential downfall of 23andMe, discussing the risks of false positives in genetic testing, concerns over data security and privacy, and the challenges of becoming a drug maker. It also highlights investors' reluctance to invest further in the company and the uncertainty surrounding its future.
Play episode from 04:26
Transcript
